Responses
Regular and young investigator award abstracts
Clinical trials in progress
401 Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.